INVESTIGATION OF CELL PROLIFERATION INHIBITION THROUGH PROTEIN TP53-INDUCIBLE GLYCOLYSIS AND APOPTOSIS REGULATOR (TIGAR) OF COMPOUNDS ISOLATED FROM Goniothalamus elegans Ast

Trần Thị Thuỳ Linh; Trần Ngọc Như Quỳnh; Trương Thanh Huyền; Lương Bội Tuyền; Nguyễn Thị Kim Tuyền; Nguyễn Tấn Khanh

doi:10.34238/tnu-jst.6350

INVESTIGATION OF CELL PROLIFERATION INHIBITION THROUGH PROTEIN TP53-INDUCIBLE GLYCOLYSIS AND APOPTOSIS REGULATOR (TIGAR) OF COMPOUNDS ISOLATED FROM Goniothalamus elegans Ast

About this article

Received: 10/08/22 Revised: 04/11/22 Published: 23/11/22

Authors

1. Tran Thi Thuy Linh, University of Medicine and Pharmacy - Hue University
2. Tran Ngoc Nhu Quynh, University of Medicine and Pharmacy - Hue University
3. Truong Thanh Huyen, University of Medicine and Pharmacy - Hue University
4. Luong Boi Tuyen, University of Medicine and Pharmacy - Hue University
5. Nguyen Thi Kim Tuyen, University of Medicine and Pharmacy - Hue University
6. Nguyen Tan Khanh , Dong A University

Abstract

Our study investigated the ability of Goniothalamus elegans Ast to inhibit growth of cancer cell, and evaluated the biological mechanism through inhibition of TIGAR protein activity. Extracts, fractions and isolated compounds were tested for the cytotoxicity of the HepG2 cancer cell line. The extract showed strong mode with IC₅₀ value of 19.74 µg/mL. Notably, the IC₅₀ values of two alkaloids, liriodenine and lysicamine were 18.12 ± 0.21 and 34.48 ± 1.21 µg/mL, respectively. The molecular docking method was used to validate the interaction between compounds and TIGAR proteins. The results indicate that liriodenine and lysicamine have strong binding affinity with TIGAR protein with values of -8.2 and -7.8 Kcal/mol, respectively. Our study shows that G. elegans extract and two compounds including liriodenine and lysicamine have the ability to inhibit the growth of HepG2 cancer cell line through the mechanism of binding to TIGAR protein. However, further experiments are required for confirming the molecular mechanisms through the TIGAR protein.

Keywords

TIGAR; TP53; Goniothalamus elegans; Liriodenine; Lysicamine

Full Text:

PDF (Tiếng Việt)

References

[1] H. Li and G. Jogl, "Structural and biochemical studies of TIGAR (TP53-induced glycolysis and apoptosis regulator)," Journal of Biological Chemistry, vol. 284, no. 3, pp. 1748-1754, 2009.

[2] K. Bensaad et al., "TIGAR, a p53-inducible regulator of glycolysis and apoptosis," Cell, vol. 126, no. 1, pp. 107-120, 2006.

[3] E. C. Cheung et al., "TIGAR is required for efficient intestinal regeneration and tumorigenesis," Developmental Cell, vol. 25, no. 5, pp. 463-477, 2013.

[4] N. Hammoudi, K. B. Ahmed, C. Garcia-Prieto, and P. Huang, "Metabolic alterations in cancer cells and therapeutic implications," Chinese Journal of Cancer, vol. 30, no. 8, pp. 508-525, 2011.

[5] J. M. Xie et al., "TIGAR has a dual role in cancer cell survival through regulating apoptosis and autophagy," Cancer Research, vol. 74, no. 18, pp. 5127-5138, 2014.

[6] S. Brogi, T. C. Ramalho, K. Kuca, J. L. Medina-Franco, and M. Valko, "Editorial: In silico Methods for Drug Design and Discovery," Frontiers in Chemistry, vol. 8, pp. 1-5, 2020.

[7] V. V. Chi, Dictionary of Vietnamese Medicinal Plants. Publishing House Medicine, Ho Chi Minh City, (in Vietnamese), 2000, pp. 1024-2015.

[8] National Institute of Medicinal Materials, List of Vietnamese medicinal plants. Science and Technics Publishing House, (in Vietnamese), 2016, pp. 92-400.

[9] M. Aslam, M. S. Ahmad, A. Mamat, M. Ahmad, and F. Salam, "Goniothalamus: Phytochemical and Ethnobotanical Review," Recent advances in biology and Medicine, vol. 2, pp. 34-47, 2016.

[10] N. Suchaichit, K. Kanokmedhakul, N. Panthama, K. Poopasit, P. Moosophon, and S. Kanokmedhakul, "A 2H-tetrahydropyran derivative and bioactive constituents from the bark of Goniothalamus elegants Ast," Fitoterapia, vol. 103, pp. 206-212, 2015.

[11] L. T. T. Tran et al., "In Silico and in Vitro Evaluation of Alkaloids from Goniothalamus elegans Ast. for Breast Cancer Treatment," Natural Product Communications, vol. 17, no. 3, pp. 1-10, 2022.

[12] N. Nordin, N. A. Majid, N. M. Hashim, M. A. Rahman, Z. Hassan, and H. M. Ali, "Liriodenine, an aporphine alkaloid from Enicosanthellum pulchrum, inhibits proliferation of human ovarian cancer cells through induction of apoptosis via the mitochondrial signaling pathway and blocking cell cycle progression," Drug design, development and therapy, vol. 9, pp. 1437-1448, 2015.

[13] C. Souza et al., "Asarone-derived phenylpropanoids and isoquinoline-derived alkaloids from the bark of Duguetia pycnastera (Annonaceae) and their cytotoxicities," Química Nova, vol. 43, no. 10, pp. 1397-1403, 2020.

[14] W. Tian, C. Chen, X. Lei, J. Zhao, and J. Liang, "CASTp 3.0: computed atlas of surface topography of proteins," Nucleic Acids Res, vol. 46, no. W1, pp. 363-367, 2018.

[15] A. Monks et al., "Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines," Journal of the National Cancer Institute, vol. 83, no. 11, pp. 757-766, 1991.

[16] T. Koltai, S. J. Reshkin, T. M. A. Carvalho, D. D. Molfetta, M. R. Greco, K. O. Alfarouk, and R. A. Cardone, “Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review,” Cancers, vol. 14, no. 10, 2022, Art. no. 2486.

[17] C. Stévigny, C. Bailly, and J. Quetin-Leclercq, "Cytotoxic and antitumor potentialities of aporphinoid alkaloids," Current Medicinal Chemistry Anticancer Agents, vol. 5, no. 2, pp. 173-182, 2005.

[18] T. K. Kwan, F. Shipton, N. S. Azman, S. Hossan, K. T. Jin, and C. Wiart, "Cytotoxic aporphines from Artabotrys crassifolius," Natural Product Communications, vol. 11, no. 3, pp. 389-392, 2016.

[19] Y. C. Wu, Y. F. Liou, S. T. Lu, C. H. Chen, J. J. Chang, and K. H. Lee, "Cytotoxicity of isoquinoline alkaloids and their N-oxides," Planta Medica, vol. 55, no. 2, pp. 163-165, 1989.

[20] C. H. Yang, M. J. Cheng, S. J. Lee, C. W. Yang, H. S. Chang, and I. S. Chen, "Secondary metabolites and cytotoxic activities from the stem bark of Zanthoxylum nitidum," Chemistry & Biodiversity, vol. 6, no. 6, pp. 846-857, 2009.

[21] S. H. Woo, M. C. Reynolds, N. J. Sun, J. M. Cassady, and R. M. Snapka, "Inhibition of topoisomerase II by liriodenine," Biochemical Pharmacology, vol. 54, no. 4, pp. 467-473, 1997.

[22] H. C. Chang, F. R. Chang, Y. C. Wu, and Y. H. Lai, "Anti-cancer effect of liriodenine on human lung cancer cells," Kaohsiung Journal of Medical Sciences, vol. 20, no. 8, pp. 365-371, 2004.

[23] Z. H. Li, J. Gao, P. H. Hu, and J. P. Xiong, "Anticancer effects of liriodenine on the cell growth and apoptosis of human breast cancer MCF-7 cells through the upregulation of p53 expression," Oncology Letters, vol. 14, no. 2, pp. 1979-1984, 2017.

DOI: https://doi.org/10.34238/tnu-jst.6350

Refbacks

There are currently no refbacks.



Remember me